[Lacosamide. A new antiepileptic drug as adjunctive therapy in patients with partial-onset seizures].
Lacosamide (Vimpat) is an aniepileptic drug with a new, dual mode of action. Lacosamide enhances slow inactivation of voltage-gated sodium channels and modulates the collapsin response mediator protein-2 (CRMP-2), a protein, which is part of neuronal signal transduction pathways and which is attributed to neuroprotection. Reduction of seizure frequency could be demonstrated in several clinical studies in patients with partial-onset seizures who received lacosamide in addition to other antiepileptic drugs.
Saussele
Tanja
T
Redaktion Medizinische Monatsschrift für Pharmazeuten, Birkenwaldstr 44, 70191 Stuttgart. tsaussele@deutscher-apotheker-verlag.de
D000081:Acetamides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000284:Administration, Oral; D000927:Anticonvulsants / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004828:Epilepsies, Partial / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D000078334:Lacosamide
D000081:Acetamides; D000927:Anticonvulsants; D000078334:Lacosamide